ENTRY       D03684                      Drug
NAME        Denosumab (USAN);
            Denosumab (genetical recombination) (JAN);
            Prolia (TN);
            Ranmark (TN);
            Xgeva (TN)
PRODUCT     PROLIA (Amgen)
            XGEVA (Amgen)
FORMULA     C6404H9912N1724O2004S50
EXACT_MASS  144631.2737
MOL_WEIGHT  144720.8225
CLASS       Anti-inflammatory
             DG01985  Disease modifying anti-rheumatic drug (DMARD)
            Musculo-skeletal system agent
             DG03232  Osteoporosis agent
REMARK      Therapeutic category: 3999
            ATC code: M05BX04
            Product: D03684<JP/US>
EFFICACY    Osteoporosis agent, Anti-RANKL antibody
  DISEASE   Osteoporosis [DS:H01593]
            Multiple myeloma [DS:H00010]
            Giant cell tumor of bone [DS:H01470]
  TYPE      Monoclonal antibody
TARGET      TNFSF11 (RANKL, CD254) [HSA:8600] [KO:K05473]
  PATHWAY   hsa04060(8600)  Cytokine-cytokine receptor interaction
            hsa04380(8600)  Osteoclast differentiation
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             M MUSCULO-SKELETAL SYSTEM
              M05 DRUGS FOR TREATMENT OF BONE DISEASES
               M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
                M05BX Other drugs affecting bone structure and mineralization
                 M05BX04 Denosumab
                  D03684  Denosumab (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Antineoplastic Adjuncts/Mitigators
               Denosumab
                D03684  Denosumab (USAN)
             Metabolic Bone Disease Agents
              RANK Ligand Inhibitor
               Denosumab
                D03684  Denosumab (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D03684  Denosumab (USAN); Denosumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Anti-inflammatory
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               D03684  Denosumab
             Musculo-skeletal system agent
              DG03232  Osteoporosis agent
               D03684  Denosumab
            Drug classes [BR:br08332]
             Antirheumatic agent
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               D03684  Denosumab
             Musculo-skeletal system agent
              DG03232  Osteoporosis agent
               D03684  Denosumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Tumor necrosis factors
                TNFSF11 (RANKL, CD254)
                 D03684  Denosumab (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D03684
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D03684
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D03684
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D03684
DBLINKS     CAS: 615258-40-7
            PubChem: 17397780
///
